A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-years in patients achieving a clinical complete response after neoadjuvant chemoradiation.